NATURAL HISTORY PREVENTION OF VIRAL HEPATITIS IN ALASKA NATIVE PEOPLE

阿拉斯加原住民病毒性肝炎的自然史预防

• 批准号: 8291863
• 负责人: Brian James McMahon
• 金额: $ 36.97万
• 依托单位: ALASKA NATIVE TRIBAL HEALTH CONSORTIUM
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-30 至 2014-06-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8291863
• 关键词: NATURAL; HISTORY; PREVENTION; VIRAL; HEPATITIS

Infections from hepatitis A virus (HAV) and hepatitis B virus (HBV) are significant problems in Alaska Natives. Hepatitis A and B vaccines have been routine immunizations in Alaska Natives since 1984 and 1994, respectively. Hepatitis A vaccine is administered to all children over 1 year of age in the US and catch-up hepatitis A virus (HAV) vaccine programs are employed in several states for all children. Hepatitis B vaccine has been administered to all neonates and children in the US for the past decade and to high risk individuals. In addition, chronic hepatitis B and C infections are significant causes of morbidity and mortality from hepatocellular carcinoma (HCC) and cirrhosis in high risk populations in the US. Alaska Natives have one of the highest rates of chronic HBV infection of any ethnic group in the US and a high rate of morbidity and mortality from hepatitis C infection. Not all persons with chronic hepatitis B or C will develop cirrhosis or HCC and the risk factors for progression are not completely elucidated. Population studies are needed to study risk factors for progression of chronic HBV and HCV. The Liver Disease and Hepatitis Program (LDHP) of the Alaska Native Tribal Health Consortium (ANTHC) working collaboratively with the Arctic Investigations Program (AIP) of the Centers for Disease Control and Prevention (CDC) has cohorts of persons who received hepatitis A and B vaccine as infants, children and adults available to determine long-term protection. In addition, the LDHP has recruited large cohorts of Alaska Natives with chronic hepatitis B or C infection. Relevance The strategy and cost effectiveness of hepatitis A and B vaccination programs depends on the supposition that these vaccines will provide long-term protection against hepatitis A and B infection. Also of concern is that persons with chronic hepatitis B or C infection are at-risk to cirrhosis and other serious liver disease. Using several Alaska Native cohorts, studies are proposed to (a) determine the duration of protection against hepatitis A and B infection in persons immunized 15-30 years ago and (b) better understand the treatment and natural history of chronic hepatitis B or C infection.

肝炎A病毒（HAV）和丙型肝炎病毒（HBV）感染是重大问题 阿拉斯加原住民。丙型肝炎和B疫苗已经是阿拉斯加当地人常规免疫 自1984年和1994年以来。丙型肝炎疫苗均针对1多个儿童。 美国的年龄和追赶肝炎病毒（HAV）疫苗计划已采用 所有儿童的几个州。丙型肝炎疫苗已施用给所有新生儿， 在过去的十年中，美国的儿童和高风险个人。 此外，慢性丙型肝炎和C感染是发病率和死亡率的重大原因 来自美国高风险种群的肝细胞癌（HCC）和肝硬化。阿拉斯加州 当地人的慢性HBV感染率是美国任何种族的最高率之一 以及乙型肝炎感染的发病率和死亡率高。并非所有患有慢性的人 丙型肝炎或C会发展出肝硬化或HCC，进展的危险因素不是 完全阐明。需要人口研究来研究进展的风险因素 慢性HBV和HCV。 阿拉斯加土著部落健康联盟的肝病和肝炎计划（LDHP） （ANTHC）与中心的北极调查计划（AIP）合作 疾病控制与预防（CDC）有许多患有肝炎和B的人群 作为婴儿，儿童和成人的疫苗可确定长期保护。此外， LDHP已招募了大量的阿拉斯加人，患有慢性丙型肝炎或C感染。 关联 丙型肝炎和B疫苗接种计划的策略和成本效益取决于 假设这些疫苗将对丙型肝炎和B提供长期保护 感染。同样令人担忧的是，患有慢性丙型肝炎或C感染的人处于风险状态 肝硬化和其他严重的肝病。使用几个阿拉斯加本地人群，研究是 提议（a）确定针对丙型肝炎和B感染的保护持续时间 15-30年前免疫的人和（b）更好地了解治疗和自然历史 慢性丙型肝炎或C感染。

项目成果

Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.

• DOI: 10.1093/infdis/jis710
• 发表时间: 2013-02
• 期刊: The Journal of infectious diseases
• 作者: G. Raczniak;L. Bulkow;M. Bruce;C. Zanis;R. Baum;Mary M Snowball;Kathy K. Byrd;U. Sharapov;T. Henn

Vaccination Status of Alaska Native Persons With Hepatitis A Virus Infection-Alaska, 1996-2018.

阿拉斯加原住民甲型肝炎病毒感染者的疫苗接种状况 - 阿拉斯加，1996-2018 年。

• DOI: 10.1093/cid/ciaa1102
• 发表时间: 2021
• 期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
• 作者: Plumb,IanD;Gounder,PrabhuP;Nolen,LeishaD;Massay,StephanieC;Castrodale,Louisa;McLaughlin,Joseph;Snowball,Mary;Homan,Chriss;Nelson,NoeleP;Singleton,Rosalyn;Bruce,MichaelG;McMahon,BrianJ
• 通讯作者: McMahon,BrianJ

Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010.

• DOI: 10.1016/j.jcv.2013.08.012
• 发表时间: 2013-10
• 期刊: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
• 作者: Tohme RA;Bulkow L;Homan CE;Negus S;McMahon BJ
• 通讯作者: McMahon BJ

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.

• DOI: 10.3402/ijch.v75.30696
• 发表时间: 2016
• 期刊: International journal of circumpolar health
• 影响因子: 1.3
• 作者: Livingston SE;Townshend-Bulson LJ;Bruden DJ;Homan CE;Gove JE;Plotnik JN;Simons BC;Spradling PR;McMahon BJ
• 通讯作者: McMahon BJ